FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely to arthrology, rheumatology, and can be used for treating rheumatoid arthritis. That is ensured by introducing human CD20 specific small modular immune-pharmaceutical (SMIP) protein in a therapeutically effective amount to the patient. The introduction is single, and the supporting treatment is not performed for approximately three months to two years after the introduction of a first single dose.
EFFECT: single introduction provides almost complete B-cell elimination and considerable prolonged rheumatoid factor level reduction in said category of patients.
24 cl, 4 tbl, 8 ex, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DECREASING B-CELL COUNT WITH USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES | 2006 |
|
RU2423381C2 |
| SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION | 2007 |
|
RU2487888C2 |
| AGENTS REDUCING B-CELL COUNT, INCLUDING CD20 ANTIBODIES OR FRAGMENTS THEREOF, FOR TREATING CHRONIC FATIGUE SYNDROME | 2009 |
|
RU2519229C2 |
| METHOD OF TREATING VASCULITIS | 2005 |
|
RU2411956C2 |
| COMBINED THERAPY FOR TREATMENT OF AUTOIMMUNE DISEASES BY USING COMBINATION OF ELIMINATING B-CELLS AND IMMUNOREGULATORY ANTIBODIES | 2001 |
|
RU2285541C2 |
| METHOD AND COMPOSITION FOR REDUCTION OF MICROMOLECULE AGGREGATION UNDER PHYSIOLOGICAL CONDITIONS | 2009 |
|
RU2563823C2 |
| COMBINATION OF ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND MOLECULE BINDING TO B-CELLS, B-CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART | 2008 |
|
RU2484845C2 |
| IMMUNOTHERAPEUTIC AGENT COMBINED WITH CD37, AND ITS COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC AGENT | 2009 |
|
RU2531754C2 |
| CD37-IMMUNOTHERAPEUTIC COMBINATION THERAPY AND USING IT | 2009 |
|
RU2526156C2 |
| METHOD OF TREATING JOINT INJURIES | 2006 |
|
RU2457860C2 |
